Contrasting Miragen Therapeutics (MGEN) & Cannabis Science (OTCMKTS:CBIS)

Cannabis Science (OTCMKTS: CBIS) and Miragen Therapeutics (NASDAQ:MGEN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation and dividends.

Valuation and Earnings

This table compares Cannabis Science and Miragen Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cannabis Science N/A N/A N/A N/A N/A
Miragen Therapeutics $3.34 million 51.30 -$12.67 million ($8.93) -0.86

Cannabis Science has higher earnings, but lower revenue than Miragen Therapeutics.

Insider and Institutional Ownership

22.6% of Miragen Therapeutics shares are held by institutional investors. 44.4% of Miragen Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and price targets for Cannabis Science and Miragen Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cannabis Science 0 0 0 0 N/A
Miragen Therapeutics 0 0 3 0 3.00

Miragen Therapeutics has a consensus price target of $24.00, indicating a potential upside of 212.50%. Given Miragen Therapeutics’ higher possible upside, analysts plainly believe Miragen Therapeutics is more favorable than Cannabis Science.

Volatility and Risk

Cannabis Science has a beta of -4.04, indicating that its stock price is 504% less volatile than the S&P 500. Comparatively, Miragen Therapeutics has a beta of 1.89, indicating that its stock price is 89% more volatile than the S&P 500.

Profitability

This table compares Cannabis Science and Miragen Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cannabis Science -953,196.00% N/A -380.46%
Miragen Therapeutics -720.38% -80.31% -64.59%

Summary

Miragen Therapeutics beats Cannabis Science on 8 of the 9 factors compared between the two stocks.

Cannabis Science Company Profile

Cannabis Science, Inc. is engaged in medical marijuana research and development. The Company works on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. The Company is involved in the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance. The Company focuses on the development of governmentally approved pharmaceuticals, including CS-TATI1, CS-S/BCC-1 and neurological therapy under study or development. The Company’s subsidiaries include Cannabis Science BV and Cannabis Science International Holding BV.

Miragen Therapeutics Company Profile

Signal Genetics, Inc. is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test. The MyPRS test is a microarray-based gene expression profile (GEP), assay that measures the expression level of specific genes and groups of genes that are designed to predict an individual’s long-term clinical outcome/prognosis, giving a basis for personalized treatment options. The Company’s MyPRS test provides a whole-genomic expression profile of a patient’s multiple myeloma (MM). The Company offers MyPRS test in its laboratory located in Little Rock, Arkansas. The Company is licensed to sell its test in all 50 states.

Receive News & Ratings for Cannabis Science Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cannabis Science Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply